2] every 21 days, plus oral estramustine
, an estrogenic drug, 280 mg t.
Neither docetaxel or estramustine
is likely to radically change the prognosis for men with advanced disease, but the findings are likely to shake many urologic oncologists out of their intellectual boxes.
Drugs that might interfere with the results of monitoring tests Antineoplastic drugs Other drugs Azacitidine Atropine Busulfan Chloral hydrate Chlorambucil Chlordiazepoxide Cisplatin Chlorpromazine Cyclophosphamide Cimetidine Cytarabine Diazepam Dacarbazine Dobutamine Dibromodulcitol Dopamine Estramustine
Ephedrine Floxuridine Fentanyl Fludarabine Haloperidol Fluorouracil Hydroxyzine Ifosfamide Meperidine Lomustine Metoclopramide Mercaptopurine Midazolam Methotrexate Morphine Streptozocin Pentobarbital Thiopeta Phenylephrine Prochlorperazine Promethazine Ranitidine Scopolamine Secobarbital Temazepam
For men with hormone-refractory prostate cancer, the use of docetaxel (Taxotere, Rhone-Poulenc Rorer) plus the nitrogen mustard estramustine
phosphate (Emcyt, Pharmacia & Upjohn) appears to help men whose prostate cancers no longer respond to treatment with synthetic estrogen and antiandrogens.
Aside from mitoxantrone and glucocorticoids, current trials are focusing on ketoconazole, estramustine
phosphate, vinblastine, and suramin (Vogelzang et al.
Chemotherapeutic agents, including cyclophosphamide, doxorubicin, 5-fluorouracil, dacarbazine, cisplatin, estramustine
, and streptozocin, alone or in combination, have produced disappointing overall response rates of approximately 30% (in those with mostly stable disease, with few complete or partial responses), with median survivals of 26 to 33 weeks.
A parallel study comparing Taxotere and estramustine
(Emcyt), an antineoplastic compound that contains estradiol and is approved for prostate cancer, to mitoxantrone and prednisone found about a 1.
4C only during treatment with Taxane/ estramustine
and was not detected before or after treatment.
A multifold increase of [Beta]III transcript expression has been shown in nonneuronal tumors, such as non-small cell lung cancer, and in ovarian and prostate cancer cell lines, particularly in those exhibiting resistance to a class of antimicrotubule (microtubule-polymerizing) drugs, such as estramustine
and paclitaxel (Taxol).
Use of estramustine
in combination with other cytotoxic agents is not recommended due to the increased risk of clinically important toxicities.